Replies to post #116542 on Biotech Values

[DewDiligence]

I presume ALNY is a winner—or at least thinks it is—insofar as it’s the issuer of the PR I posted. To a first-order approximation, the investment consequence of this settlement is nil, IMO.

[DewDiligence]

ALNY is off more than 40% in the past year and has an enterprise value of only $200M. Does anyone here find the stock attractive at this valuation?

They reported 1Q11 results today:
http://finance.yahoo.com/news/Alnylam-Pharmaceuticals-bw-1042593757.html?x=0&.v=1 .